Shi Bian, Chu Junfeng, Huang Tao, Wang Xiaoqian, Li Qiujian, Gao Qilong, Xia Qingxin, Luo Suxia
Department of Integrated Traditional Chinese and Western Medicine, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Department of Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
Front Oncol. 2021 Oct 29;11:771488. doi: 10.3389/fonc.2021.771488. eCollection 2021.
Macrophage-targeting therapies have become attractive strategies for immunotherapy. Deficiency of MARCO significantly inhibits tumor progression and metastasis in murine models of pancreatic cancer. However, the role of MARCO in patients with pancreatic cancer remains unclear. In the present study, we analyzed tumor-associated macrophage (TAM)-related changes using the Cancer Genome Atlas database. We observed a significant enrichment of M2 macrophages in pancreatic cancer tissues. We found that several pro-tumor markers are increased in cancer tissues, including CD163, CD206, SIRPα, LILRB1, SIGLEC10, AXL, MERTK, and MARCO. Crucially, MARCO is highly or exclusively expressed in pancreatic cancer across many types of solid tumors, suggesting its significant role in pancreatic cancer. Next, we investigated the expression of MARCO in relation to the macrophage marker CD163 in a treatment-naïve pancreatic cancer cohort after surgery (n = 65). MARCO and CD163 were analyzed using immunohistochemistry. We observed increased expression of CD163 and MARCO in pancreatic cancer tissues compared with paracancerous tissues. Furthermore, we observed a large variation in CD163 and MARCO expression in pancreatic cancer tissues among cases, suggesting the heterogeneous expression of these two markers among patients. Correlation to clinical data indicated a strong trend toward worse survival for patients with high CD163 and MARCO macrophage infiltration. Moreover, high CD163 and MARCO expression negatively affected the disease-free survival and overall survival rates of patients with pancreatic cancer. Univariate and multivariate analysis revealed that CD163 and MARCO expression was an independent indicator of pancreatic cancer prognosis. In conclusion, high CD163 and MARCO expression in cancer tissues is a negative prognostic marker for pancreatic cancer after surgery. Furthermore, anti-MARCO may be a novel therapy that is worth studying in depth.
靶向巨噬细胞的疗法已成为免疫治疗的有吸引力的策略。在胰腺癌小鼠模型中,MARCO的缺乏显著抑制肿瘤进展和转移。然而,MARCO在胰腺癌患者中的作用仍不清楚。在本研究中,我们使用癌症基因组图谱数据库分析了肿瘤相关巨噬细胞(TAM)相关的变化。我们观察到胰腺癌组织中M2巨噬细胞显著富集。我们发现癌症组织中几种促肿瘤标志物增加,包括CD163、CD206、SIRPα、LILRB1、SIGLEC10、AXL、MERTK和MARCO。至关重要的是,在多种实体瘤中,MARCO在胰腺癌中高度或特异性表达,表明其在胰腺癌中起重要作用。接下来,我们在未经治疗的术后胰腺癌队列(n = 65)中研究了MARCO与巨噬细胞标志物CD163的表达关系。使用免疫组织化学分析MARCO和CD163。与癌旁组织相比,我们观察到胰腺癌组织中CD163和MARCO的表达增加。此外,我们观察到病例间胰腺癌组织中CD163和MARCO表达存在很大差异,表明这两种标志物在患者中表达异质性。与临床数据的相关性表明,CD163和MARCO巨噬细胞浸润高的患者生存预后较差的趋势明显。此外,高CD163和MARCO表达对胰腺癌患者的无病生存率和总生存率产生负面影响。单因素和多因素分析显示,CD163和MARCO表达是胰腺癌预后的独立指标。总之,癌症组织中高CD163和MARCO表达是胰腺癌术后的不良预后标志物。此外,抗MARCO可能是一种值得深入研究的新疗法。